Related Experiment Video
Updated: Aug 6, 2026

Enhanced Oil Recovery using a Combination of Biosurfactants
Published on: June 3, 2022
Lung surfactants
1Emory Crawford Long Hospital, Atlanta, GA, USA.
Insights
Exogenous lung surfactants significantly reduce respiratory distress syndrome (RDS) in infants. Natural surfactants show better outcomes than synthetic ones, though synthetic options offer supply advantages.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pharmacology
Background:
- Respiratory distress syndrome (RDS) is a major concern in premature infants.
- Exogenous lung surfactants are crucial for managing neonatal RDS.
Purpose of the Study:
- To review the pharmacology, clinical efficacy, and cost of exogenous lung surfactants.
- To compare the effectiveness of natural and synthetic surfactant preparations.
Main Methods:
- Review of existing literature on exogenous lung surfactants.
- Analysis of clinical trial data comparing different surfactant types.
Main Results:
- Exogenous surfactants, particularly natural ones, reduce RDS incidence and complications.
- Natural surfactants demonstrate superior outcomes in reducing ventilator support, pneumothorax, bronchopulmonary dysplasia, and mortality compared to synthetic surfactants.
- Rescue therapy within two hours of birth is as effective as prophylaxis for most premature infants.
Conclusions:
- Exogenous pulmonary surfactants are vital in neonatal care, significantly improving outcomes for infants with RDS.
- Natural surfactants generally outperform synthetic options in clinical efficacy, despite synthetic agents offering advantages in supply and consistency.
- Advancements in surfactant therapy and ventilatory care have dramatically improved infant survival rates.
Purpose:
The pharmacology, clinical efficacy, and cost considerations of exogenous lung surfactants are reviewed.
Summary:
Exogenous pulmonary surfactants, along with advancements in ventilatory care, have significantly reduced the incidence of respiratory distress syndrome (RDS) and its related complications in infants. The following exogenous surfactants are approved for the prophylaxis and treatment (rescue) of neonatal RDS: beractant, a modified natural surfactant; calfactant and poractant, both natural surfactants; and colfosceril, a synthetic surfactant that is not currently available in the United States. Lucinactant, a synthetic surfactant, is under investigation and received approvable status from the Food and Drug Administration in February 2005. The surfactants are delivered directly to their site of action, and only small amounts reach the systemic circulation. Bioavailability to the distal airways and alveoli depends on the method of delivery, the stage and severity of pulmonary disease, and the properties of the particular surfactant. According to data from clinical trials, the use of exogenous surfactant therapy for rescue within the first two hours of life appears to be as efficacious as prophylaxis in most premature infants.
Conclusion:
Comparative trials of surfactants have proven the efficacy of both synthetic and natural surfactants in the prevention and treatment of RDS. However, these trials have universally demonstrated greater reduction in the immediate need for ventilator support in infants who receive natural surfactants. Natural preparations cause less pneumothorax, bronchopulmonary dysplasia, and mortality compared with synthetic preparations. Synthetic agents offer the potential advantages of an unlimited supply with consistent pharmaceutical quality and no risk of transmitting infectious disease or causing immunologic sensitization.
Related Concept Videos
Surface Active Agents
Breathing
Micelles
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Surface Tension of Fluid
Surface tension varies with...
Colloids

